Botanix Pharmaceuticals Ltd has released a press release.
Botanix Announces Top Line BTX 1204 Atopic Dermatitis Data
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Antimicrobial Platform Update and Launch of BTX 1801 Study
- Botanix Initiates BTX 1702 Rosacea Study
- Botanix Announces De-scheduling of Synthetic CBD
- Botanix Announces BTX 1503 Data and Progression to Phase 3
- BOT Receives Grant for Synthetic Cannabidiol Analog Program
Later from Botanix Pharmaceuticals
- Botanix Provides Update on Development Activities
- Botanix Provides Update on Development Activities Amended
- FDA Grants BTX 1801 QIDP Designation Status
- BTX 1503 End of Phase 2 Milestone with FDA
- Response to ASX Aware Query
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals